Current Applications for Prostate-Specific Antigen Doubling Time

Michelle L. Ramírez, Eric C. Nelson, Ralph W deVere White, Primo N Lara, Christopher P Evans

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: To review the current status of prostate-specific antigen doubling time (PSADT) as it pertains to the evolution of prostate cancer (PCa), specifically assessing its role in the following four stages: before diagnosis, prior to definitive treatment, following treatment including salvage therapy after recurrence, and lastly, after onset of androgen-insensitive PCa. Methods: We searched PubMed literature for current articles on PSADT using the key words listed for this review and, where possible, selected those with significant levels of evidence that were deemed relevant, seminal, or controversial. We summarized the data regarding PSADT as a marker for diagnosis and disease characterization, as well as a predictor of progression, response to treatment, and mortality. Results: PSADT may offer an advantage in providing a more dynamic picture of tumor behavior, providing clues regarding the relative aggressiveness of the underlying pathology. Evidence points toward a role for PSADT in the management of PCa, specifically in active surveillance, disease recurrence after treatment, and in androgen-independent PCa. PSADT is an important prognostic factor that may serve as an auxiliary end point for cancer-specific survival; however, optimal cut-off points denoting risk remain debatable. Conclusions: PCa management requires risk stratification with a combination of variables, PSADT being one of the most reliable predictors. It is now a parameter included in many predictive nomograms and in treatment guidelines for expectant management and salvage therapy.

Original languageEnglish (US)
Pages (from-to)291-302
Number of pages12
JournalEuropean Urology
Volume54
Issue number2
DOIs
StatePublished - Aug 2008

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Salvage Therapy
Androgens
Time Management
Therapeutics
Recurrence
Nomograms
Risk Management
PubMed
Neoplasms
Guidelines
Pathology
Mortality

Keywords

  • Active surveillance
  • Androgen-independent prostate cancer
  • Biochemical recurrence
  • Biopsy
  • Expectant management
  • Prostate cancer
  • Prostate-specific antigen doubling time
  • Prostate-specific antigen kinetics
  • Salvage therapy

ASJC Scopus subject areas

  • Urology

Cite this

Current Applications for Prostate-Specific Antigen Doubling Time. / Ramírez, Michelle L.; Nelson, Eric C.; deVere White, Ralph W; Lara, Primo N; Evans, Christopher P.

In: European Urology, Vol. 54, No. 2, 08.2008, p. 291-302.

Research output: Contribution to journalArticle

@article{3dddc7fd975b45c8b6a775b8195a52c1,
title = "Current Applications for Prostate-Specific Antigen Doubling Time",
abstract = "Objective: To review the current status of prostate-specific antigen doubling time (PSADT) as it pertains to the evolution of prostate cancer (PCa), specifically assessing its role in the following four stages: before diagnosis, prior to definitive treatment, following treatment including salvage therapy after recurrence, and lastly, after onset of androgen-insensitive PCa. Methods: We searched PubMed literature for current articles on PSADT using the key words listed for this review and, where possible, selected those with significant levels of evidence that were deemed relevant, seminal, or controversial. We summarized the data regarding PSADT as a marker for diagnosis and disease characterization, as well as a predictor of progression, response to treatment, and mortality. Results: PSADT may offer an advantage in providing a more dynamic picture of tumor behavior, providing clues regarding the relative aggressiveness of the underlying pathology. Evidence points toward a role for PSADT in the management of PCa, specifically in active surveillance, disease recurrence after treatment, and in androgen-independent PCa. PSADT is an important prognostic factor that may serve as an auxiliary end point for cancer-specific survival; however, optimal cut-off points denoting risk remain debatable. Conclusions: PCa management requires risk stratification with a combination of variables, PSADT being one of the most reliable predictors. It is now a parameter included in many predictive nomograms and in treatment guidelines for expectant management and salvage therapy.",
keywords = "Active surveillance, Androgen-independent prostate cancer, Biochemical recurrence, Biopsy, Expectant management, Prostate cancer, Prostate-specific antigen doubling time, Prostate-specific antigen kinetics, Salvage therapy",
author = "Ram{\'i}rez, {Michelle L.} and Nelson, {Eric C.} and {deVere White}, {Ralph W} and Lara, {Primo N} and Evans, {Christopher P}",
year = "2008",
month = "8",
doi = "10.1016/j.eururo.2008.04.003",
language = "English (US)",
volume = "54",
pages = "291--302",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Current Applications for Prostate-Specific Antigen Doubling Time

AU - Ramírez, Michelle L.

AU - Nelson, Eric C.

AU - deVere White, Ralph W

AU - Lara, Primo N

AU - Evans, Christopher P

PY - 2008/8

Y1 - 2008/8

N2 - Objective: To review the current status of prostate-specific antigen doubling time (PSADT) as it pertains to the evolution of prostate cancer (PCa), specifically assessing its role in the following four stages: before diagnosis, prior to definitive treatment, following treatment including salvage therapy after recurrence, and lastly, after onset of androgen-insensitive PCa. Methods: We searched PubMed literature for current articles on PSADT using the key words listed for this review and, where possible, selected those with significant levels of evidence that were deemed relevant, seminal, or controversial. We summarized the data regarding PSADT as a marker for diagnosis and disease characterization, as well as a predictor of progression, response to treatment, and mortality. Results: PSADT may offer an advantage in providing a more dynamic picture of tumor behavior, providing clues regarding the relative aggressiveness of the underlying pathology. Evidence points toward a role for PSADT in the management of PCa, specifically in active surveillance, disease recurrence after treatment, and in androgen-independent PCa. PSADT is an important prognostic factor that may serve as an auxiliary end point for cancer-specific survival; however, optimal cut-off points denoting risk remain debatable. Conclusions: PCa management requires risk stratification with a combination of variables, PSADT being one of the most reliable predictors. It is now a parameter included in many predictive nomograms and in treatment guidelines for expectant management and salvage therapy.

AB - Objective: To review the current status of prostate-specific antigen doubling time (PSADT) as it pertains to the evolution of prostate cancer (PCa), specifically assessing its role in the following four stages: before diagnosis, prior to definitive treatment, following treatment including salvage therapy after recurrence, and lastly, after onset of androgen-insensitive PCa. Methods: We searched PubMed literature for current articles on PSADT using the key words listed for this review and, where possible, selected those with significant levels of evidence that were deemed relevant, seminal, or controversial. We summarized the data regarding PSADT as a marker for diagnosis and disease characterization, as well as a predictor of progression, response to treatment, and mortality. Results: PSADT may offer an advantage in providing a more dynamic picture of tumor behavior, providing clues regarding the relative aggressiveness of the underlying pathology. Evidence points toward a role for PSADT in the management of PCa, specifically in active surveillance, disease recurrence after treatment, and in androgen-independent PCa. PSADT is an important prognostic factor that may serve as an auxiliary end point for cancer-specific survival; however, optimal cut-off points denoting risk remain debatable. Conclusions: PCa management requires risk stratification with a combination of variables, PSADT being one of the most reliable predictors. It is now a parameter included in many predictive nomograms and in treatment guidelines for expectant management and salvage therapy.

KW - Active surveillance

KW - Androgen-independent prostate cancer

KW - Biochemical recurrence

KW - Biopsy

KW - Expectant management

KW - Prostate cancer

KW - Prostate-specific antigen doubling time

KW - Prostate-specific antigen kinetics

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=45849110599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849110599&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2008.04.003

DO - 10.1016/j.eururo.2008.04.003

M3 - Article

C2 - 18439749

AN - SCOPUS:45849110599

VL - 54

SP - 291

EP - 302

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 2

ER -